Johnson & Johnson CEO Alex Gorsky speaks to CNBC's Meg Tirrell about his company's expectations for 2017, Donald Trump's impact on the drug industry and potential M&A plans.
A judge ruling blocks Sanofi and partner Regeneron from selling their cholesterol drug, which is a victory for Amgen. CNBC's Meg Tirrell reports.
CNBC's Meg Tirrell reports on how first responders deal with emergency opioid overdose calls, and potential headwinds.
CNBC's Meg Tirrell reports on how high drug prices are limiting access to life-saving drugs such as Naloxone.
CNBC's Meg Tirrell reports the latest on the war on drug prices as several drugs are seeing their prices hiked since the start of the year.
CNBC's Meg Tirrell reports that one analyst is raising a red flag on Biogen due to the incredibly high price of a new drug to treat a rare genetic disease in children.
So-called "superbugs" "threaten the achievements of modern medicine," according to the World Health Organization.
CNBC's Meg Tirrell reports on what Donald Trump's push to lower drug prices may mean for the pharmaceutical industry.
CNBC's Meg Tirrell speaks to Acorda Therapeutics CEO Ron Cohen about Trump's comments against drug prices, and the current state of the biotech industry.
CNBC's Dominic Chu reports the latest on DOJ charges against Heritage Pharmaceuticals executives involving a generic drug pricing scheme.
Short-seller Andrew Left, Citron Research, discusses his tweet directing Donald Trump's attention towards Express Scripts, and his other shorts in the pharmaceutical space.
Short-seller Andrew Left, Citron Research, explains why Express Scripts is the "Philidor of the pharma industry," referring to Philidor Rx Services' alleged misconduct with Valeant Pharmaceuticals.
Shares of Express Scripts plunge following short-seller Andrew Left's series of tweets taking aim at the company. CNBC's Meg Tirrell reports.
Les Funtleyder, ESquared Asset Management, weighs in on Donald Trump's attack against drug prices, and the healthcare sector.
CNBC's Meg Tirrell reports on who may be leading the FDA under a Trump presidency.
Chris Meekins, FBR research analyst, discusses three reasons to ignore Donald Trump's comments against the current drug prices.
Kenneth Frazier, the CEO of pharmaceutical giant Merck, says Trump's call to revamp Obamacare could prove useful.
CNBC’s Meg Tirrell talks to Kenneth Frazier, Merck CEO, at the fifth annual Forbes Healthcare Summit in New York about the future of drug pricing under the Trump administration as well as Alzheimer’s research.
Ravi Mehrotra, MTS Partners, and CNBC's Meg Tirrell discuss the high cost of pharmaceuticals in America and what can be done to rein prices in.
CNBC's Meg Tirrell speaks with Alkermes Chairman & CEO Richard Pops at the Partnering for Cures conference about drug pricing, his company's new depression drug and the opioid epidemic.